Inhaled Therapies to Treat Respiratory Disease Locally

Beyond PRS-060, a first-in-class inhaled IL4R⍺ antagonist for the treatment of asthma, we are advancing four early-stage programs as part of our collaboration with AstraZeneca. For those four programs, we are responsible for the initial discovery of novel Anticalin® proteins, after which AstraZeneca is responsible for continued development. We have the option to co-develop two of these programs at a pre-defined preclinical stage and to co-commercialize these programs in the U.S., whereas AstraZeneca will be responsible for the development and commercialization of the other programs worldwide.

About Our AstraZeneca Partnership